click company/industri name report summari
price estim chang
energ ecosystem util week takeaway maintain buy pt
issu cloud opportun bempeg still hold promis reiter buy
lower pt
defin connect fit categori initi buy pt
preview continu focu bigger pictur defens still seem hold
expect in-lin preliminari guid put take buy pt
bit deceler reacceler think hold pt
see pathway revit takeaway road reiter buy rate
biomed devic servic
what med-tech intrigu upcom ew print
hcit servic weekli wrap-up
summari publish mon-fri includ report publish sinc recent edit pleas refer individu report specif public price date
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect invest analyst person independ object view
design invest relev issuer discuss herein
research report uk produc canaccord genuiti limit authoris regul financi conduct author fca report
european issuer non-independ research market commun market abus regul fca conduct busi rule
canaccord genuiti australia limit australian affili global capit market group canaccord genuiti group inc cf tsx recommend
opinion express research report accur reflect analyst person independ object view design invest
import inform pleas see import disclosur begin page document
back index
energ ecosystem util week takeaway
maintain buy pt
acquisit integr larg complet silverspr network
platform start demonstr synergist benefit combin powerhous
continu find condit place optim potenti combin competit
posit attract valuat etc stay construct
recent attend itron util week iuw compani annual customer-focus
confer attende short convers product tour give us
increas convict underli strategi core posit ahead
view period acceler chang broader util industri also
opportun meet manag ceo tom deitrich cfo joan hooper
find key initi point ahead report increas target
find near-term fundament support improv visibl
first find near-term momentum particularli robust driven na evidenc
recent import sizabl win recal
previous select network colorado view latest
deal valid power best-of-bre capabl post-merg xcel set
bring edg intellig enabl latest smart meter across territori
next five year xcel serv electr ga custom state
importantli xcel also partner broader iot applic load
disaggreg dr prepay plan submet ev charg etc expect
similar type deal follow
iuw year theme power commun stay focus
help util custom address grow challeng cyber threat age
infrastructur workforc natur disast wake wildfir rapidli chang
grid etc enabl seiz futur opportun still far behind area
like user expect find compani uniqu posit build
legaci innov trust partner role expect broader industri
enter period rapidli acceler chang vs histor util pace come
year requir sizabl invest drive agil flexibl product centric
detail pictur
report close novemb remain
comfort revs/adjust ep estim vs street
expect target stay firmli track annual book
fulli offset bill along continu impress de-lever
valuat price target calcul use ev/ebitda
multipl ebitda estim equat pe multipl
risk utility-centr sale cycl long lumpi subject regulatori review along
major integr effort increas competit
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
issu cloud opportun
bempeg still hold promis reiter buy lower pt
wake manufactur issu confound bempegaldesleukin
dataset manufactur concern skeptic like remain
overhang bristol-my collabor on-going initi registr
trial melanoma bladder renal cancer put potenti launch track
though expect formal collabor downsiz overal given
establish proof-of-concept cautious optimist resolv
manufactur issu establish bempeg promis contend cancer
immunotherapi reiter buy lower pt reflect increas risk
decreas scope
issu complic assess bempeg efficaci august disclos
two lot bempeg use manufactur use sub-optimal batch
in-process intermedi deem reason melanoma respons
rate decay first second cohort present vs
rr patient start defect lot respons rate rr vs
start good lot bempeg defect lot across
arm includ melanoma renal cell cancer urotheli cancer non-smal
first patient propel combo trial pembrolizumab atezolizumab
use lot almost exclus howev reveal combin use lot
appreci drug product less defin earlier-stag trial
develop control strategi reliabl test limit varianc go forward
accept fda also appoint new leadership suppli chain
fda grant bempeg breakthrough melanoma consist mechan
bempeg melanoma respons deepen time achiev cr
vs
march respons on-going median studi
fda analysi registr melanoma data clinic trial
evalu patient show improv time event benefit greater depth
respons conclud maxim tumor reduct import
bm collabor continu albeit reduc scale origin collabor
indic tumor type registr trial initi within month
effect date call state registr trial start
process start recent revis number indic
better alloc compani resourc registr trial current underway
melanoma uc mrcc nsclc expans cohort continu
expect addit registr trial like would expand util tumor type
registr trial alreadi on-going emphas bm remain commit
work pivot trial patient dose lot
upcom mileston expect updat melanoma
rcc esmo io dec expect pivot data updat
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
initi coverag
defin connect fit categori initi buy
pt
modest start pop-up shop mall short hill millburn nj peloton
grown showroom subscrib expect strong growth
ahead compani uniqu conveni in-hom connect fit model appeal
wealthi household value-consci consum hope save
fee boutiqu fit class long term think peloton abl
reinvest subscript revenu platform brand fundament chang
way household engag fit stock pressur sinc ipo price like reflect
gener market weak eschew oper loss
impact recent ipo see opportun set view
conserv forecast compel busi model limit direct competit
peloton make larg market opportun even larger estim global
fit market billion billion spent gym membership
small fraction go in-hom fit boutiqu fit rise
claim gym member us number roughli
coincid peloton target us middle- upper-incom household
sampl interest peloton product current price point
peloton member market fit equip time purchas
suggest ampl room move needl showroom advertis
opportun larger still account canada uk germani current
intern market compani
extend leadership via four imper high-touch logist model manag
fund omni-channel market cost commun build origin content
model pillar becom stronger self-reinforc scale
taken togeth help compani continu grow lead segment
busi model provid foundat growth peloton gener enough gross
profit cfp sale larg cover sale market expens enabl rapid
subscrib growth estim compound-annual-growth-rate sub greater
invest key area like content logist heavi invest
year along line two new flagship studio materi increas fulfil
capac new headquart contribut capital-expenditure ebitda
margin trough year see expand subscript contribut
margin year help scale oper leverag
lead way steadi ramp toward ebitda profit
valuat price target price target base forward revenu
support dcf sotp valuat
risk peloton may prove expens middle-incom household limit
modal may work well in-hom model limit appeal
consum investor may appreci peloton long ramp profit limit
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
preview continu focu bigger pictur
defens still seem hold maintain
investor need see clearer articul specif action strategy/offens
report market open tuesday past
quarter note core multipl sclerosi ms franchis continu hold
least term us prescript share see page similarli
believ spinraza spinal muscular atrophi remain well posit nv
gene therapi zolgensma continu launch ramp roche/ptct oral risdiplam
wait wing said believ investor focus
perform unless perceiv bad investor recal
solid think major investor believ need someth
anyth step rut stock failur aducanumab
follow lesser extent elenbecestat alzheim diseas ad
recent departur michael ehler evp replac veteran
al sandrock continu chief medic offic role believ investor
clamor see specif strategi exist pipelin assets/focu area
externally-focus busi develop
sever underappreci pipelin event end riski
tecfidera/m defens biib/alk vumer diroximel fumar decent
gastrointestin toler data vs tecfidera late receiv tent
approv remain track final approv sever pipelin
catalyst come end see tabl detail
note investor remain skeptic even non-ad relat indic
also present signific challeng separ surpris absenc
detail aducanumab phase failur upcom clinic trial alzheim
diseas ctad meet san diego ca
could beat ep consensu
revenu ep estim unchang go result
model substanti unchang well ep estim
consensu company-compli believ main sourc ep delta
could modestli lower estim revenu gross profit
higher oper expens off-set somewhat lower tax rate share
count assumpt tabl detail estim vs consensu line item
maintain hold remain tough recommend sole valuat
pend updat call maintain price target
pt impli decent upsid valuat ep appear attract
believ sever move part investor skeptic give us paus
stock recal also unlik sever major biopharma peer pay
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
technolog media telecom
expect in-lin preliminari guid put take
continu like risk reward setup next quarter think
stock sustain current multipl grow earn high teen expect
manag preliminari outlook provid earn call
rel line long-term guidanc could caveat
year via put take posit side total payment volum tpv
continu get boost strong growth activ user fuel one touch
recent strateg partnership like mercadolibr venmo continu
show strong user growth dont expect signific contributor top
line yet longer term like compani foray china via recent gopay
deal flip side payment volum declin like acceler strateg
relationship expir although impact mitig reduc contribut
overal payment volum margin declin transact take rate could result less
revenu upsid next year although fix cost leverag continu buoy adjust
earn growth net net believ posit deliv high teen earn
growth pullback provid downsid protect shorter
expect rel soft land declin off-set merchant
use one touch ebay repres approxim tpv expect
declin tpv end impli dollar base payment volum
declin approxim million equival low singl digit tpv growth
headwind next year view risk well understood point associ
 deceler look unless larger expect offset
much declin highlight torrid growth onetouch drive
mobil tpv driven million subscrib million merchant
strateg partnership start contribut next year partnership
mercadolibr go live next year estim could add sever point tpv
growth user two platform abl purchas good servic via
also send money via payment also explor
increment payment collabor includ develop
digit wallet given scale think continu success forg
strateg partnership like mercadolibr
entri china could game changer long run acquir control
stake chines payment processor gopay beat card network visa
mastercard china licens third parti payment processor gopay allow
transact yuan could eventu drive meaning cross-bord payment
volum direct believ chines govern view paypal mean
boost chines e-commerce export said
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
bit deceler reacceler think
hold pt
think squar one better long-term model across payment landscap
solid critic mass merchant side close consum
think squar could eventu one holist payment ecosystem
said shorter term believ stock continu trade base
growth trajectori payment volum still captur merchant side
equat last quarter payment volum growth deceler
recent convers compani clearli underscor busi
ramp invest high roi sale market effort think effort
payoff point next year backdrop increment intens
competit think payment volum growth like deceler bit
point would like see squar report payment volum includ transact
come app believ consum side equat provid
holist view overal payment volum flow squar ecosystem
caviar divest app move front center believ
app monet potenti platform avail
expect result underscor squar evolv busi strategi
traction app off-set sale market spend
reacceler merchant payment volum thu gravit toward print
character solid revenu growth in-line earn continu scrutini
trajectori payment volum expect guidanc year maintain
expect detail manag invest spend roi thought
last quarter divestitur caviar made sens make even sens us
believ manag lay compel case boost invest
drive growth attract roi payment
food deliveri also believ margin competit merchant po
like increas believ first data clover system see materi increas
distribut next year asset acquir addit
also hear america may roll po system support
larg merchant busi well net net acceler invest spend grab market
share drive earn make sens us squar right
still like squar holist busi model lot continu think squar
furthest along develop virtuou payment circl dollar flow within
payment ecosystem consum merchant back also
believ app emerg profit platform uniqu
posit direct deposit capabl versu platform venmo
app potenti move toward top wallet account balanc easili trend
higher card provid plastic debit card take app balanc
drive attract interchang via purchas good servic
back index
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
diagnost tool
back index
see pathway revit takeaway
road reiter buy rate pt
recent privileg host biosystem ceo john mcdonough two
day investor meet come meet sens recent
kicked-in subsidi medicar bacteria panel biggest near-term
catalyst though wait result see earli impact
encourag subsidi like incentiv custom order
test like set acceler order also
bigger appreci futur opportun believ
expand util flexibl platform technolog reiter buy rate
big new catalyst august grant approv new technolog
add-on payment panel amount
drop price discount list price went
effect octob earli judg impact indic
user awar add-on payment estim
patient suspect sepsi cover medicar would elig
payment time estim could appli mani
patient assum privat payor follow
revamp sale forc indic turn direct sale forc
past year rep fleet target hospit antibiot stewardship
committe believ result faster sale cycl new rep
experienc sell antibiot hospit stewardship committe
barda recal august sign agreement barda
largest diagnost contract ever fund barda indic barda highli
interest develop expand bacteria panel cover
bacteri target vs cover given abil guid de-
escal broad-spectrum antibiot expect initi payment convert
revenu next month remain convert revenu
upon achiev mileston option period within next year
longer-than-expect custom valid led slower-than-expect
ramp indic meet sever hospit run mini-
valid studi evalu use emerg depart
patient icu patient cancer patient extend custom
valid period month month roughli account live
test patient number expect doubl next two quarter
earli interest appear strong recent launch
panel research use expect launch ce-mark version eu
begin enrol clinic trial earli trial like
take month complet fda breakthrough statu pathway
start talk fda thu time fluid believ fda-clear version
panel like hit around indic meet believ
may also elig payment view posit
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
what med-tech intrigu
bottom line buy-rat ew would long print wed see
higher probabl upsid top- bottom-lin quarter sinc
tavr intermedi risk cycl commenc wit takeaway tct
see note bullish regard tavr growth trend immedi follow
low-risk approv earn side tavr upsid ew could immens
accret ep estim estim increment om tavr
upsid could buy-rat see offset put take
portend in-lin print guid thu recommend maintain long-term posit
call
separ registr open medic technolog
diagnost forum novemb westin grand central new york
citi registr link present compani list page anticip
nearli med-tech firm privat public set event forum
investor discov emerg growth compani across med-tech spectrum
earn page follow preview coverag name print result
week includ buy pt ew
buy pt hold pt
valuat multipl trend med-tech
large-cap med-tech market cap trade slightli wk/wk p/
 vs multipl last week group continu trade near high end
multi-decad peak/trough level exclud depth financi crise
rel year respect
mid-cap med-tech market cap valuat also trade wk/wk end
week price-to-earnings multipl vs multipl last week mid-cap current
trade well midpoint histor peak/trough rang
small-cap med-tech market cap trade wk/wk ev/
sale median multipl vs multipl last week group current trade
midpoint multi-decad peak/trough rang respect rel
year
back index
biomed devic servic
price close busi oct
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
price close busi oct
hcit servic weekli wrap-up
healthcar servic news perspect
highlight effort shift care higher-cost lower-cost care
set compani earn call manag highlight effort
make care afford shift servic imag surgeri specialti
drug administr lower-cost outpati care set specif ceo said
consider excess spend care deliv sub-optim high-cost
set provid higher-qu consumer-respons
cost-effect site allud opportun move medic spend
compani commerci busi lower-cost set
expand effort high-cost servic year-end strategi expect
gener cost save industry-wid trend benefit
crh medic chrm buy ambulatori gi anesthesia servic segment
bio buy home infus therapi
industri trend toward center excel high-valu provid network
continu increas time time expect payer employ
increasingli contract specif provid order drive lower cost improv
qualiti care view illustr three recent exampl wall street journal
articl week detail amazon travel program send employe diagnos
cancer citi lo angel allud bullet
discuss earn call direct beneficiari high perform
provid improv qualiti lower cost state high perform provid
deliv care lower cost across entir book-of-busi effort could
drive annual cost save recent announc kidney transplant
benefit mayo clinic assum trend illustr three
exampl continu believ premier buy would greatest beneficiari
current invest develop payer/employ high-valu network
offer gener revenu current compani anticip area
long-term growth driver
omada health partnership abbott strateg invest intermountain
last thursday omada announc strateg invest intermountain
healthcar amount disclos omada intermountain relationship date back
diabet prevent program launch intermountain begin
intermountain offer omada program benefit employe
previous june omada rais round led wellington monday
omada abbott detail partnership abbott freestyl libr
exclus cgm devic omada type diabet offer data cgm
integr omada diabet tech-en coach program
show continu growth fl medicaid last week state medicaid agenc
fl publish sept enrol data manag care program lighthous
health region enrol increas m/m
market share increas best assurance/vivida
region enrol increas m/m market share increas
miami children health region enrol
increas m/m market share increas
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
price close busi octob
amazon amazon continu expand free one-day ship program prime
member investor focus boost new program might provid
on-line store revenu growth magnitude/timelin invest need
support expect compani see y/i increas former
y/i contract oper margin result latter
particular interest compani commentari surround report eas
restrict remov minimum free-ship elig low price cpg
follow recent leadership transit saw ceo devin wenig step
follow discuss new board director investor focus
updat interim ceo scott schenkel ebay on-going strateg review
could includ sale stubhub classifi busi forecast
anoth quarter solid activ buyer growth y/i expect marketplac gmv
declin y/i headwind relat recent initi sale tax remain
snap snap ad impress dau last quarter heel new
android applic releas new ar lens drove user growth
quarter stronger video content launch sever new premium game
compani like benefit tailwind still
expect y/i dau growth bring total global dau count product
innov continu attract new advertis expect y/i ad revenu
growth juli snap launch instant creat ad tool automat
pull imag compani websit app suggest templat base
brand object target audienc also expect manag provid
addit detail newli announc dynam design retail
dtc brand
twitter expect low-teen mdau growth heel three consecut
quarter acceler growth compani on-going platform health initi
lead improv engag trend forecast deceler
advertis revenu growth due compani decis phase certain
legaci ad format difficult comp quarter recent convers
industri particip suggest becom popular choic brand
look diversifi spend among social platform due uniqu
time relev offer
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
last week saw equiti fix incom market stay narrow trade rang
welcom sign stabil given potenti disloc news backdrop
corporate-profit report brexit negoti trade-war commentari chao syria
continu polit upheav washington head week addit
russel transport index outperform made
new high bare cyclic beat defens sector chang said
one area concern move back posit slope yield curv follow
initi invers treasuri curv concern yield
curv invert move back posit slope final warn recess
subsequ bear market immin
dont let fact get way good stori although true last three
recess began posit slope ust yield curv mislead best
suggest initi move back posit slope offer evid end near figur
would make follow observ three pre-recess period use
recess bear market ust yield curv initi invert
week come invers next week
ralli addit next month figur
recess bear market ust yield curv initi invert week
come invers next week ralli
addit next month figur must note
nasti drawdown quickli revers follow initi move back posit
recess ust yield curv saw origin invers week
follow initi move back posit territori
 ralli addit peak cycl
summari although market nervou messag ust yield
curv prospect econom growth lot time upsid
peak cycl recess believ stage next leg higher
toward target set driven continu accommod
global monetari polici less poor global econom data ultim lead
reacceler news tweet fatigu
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
